MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Core Insights - MetaVia Inc. announced that an abstract on Vanoglipel (DA-1241), a GPR119 agonist, has been accepted for presentation at the AASLD Liver Meeting 2025 [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and Vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] - DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, showing potential for superior weight loss and glucose control [4] Product Details - Vanoglipel (DA-1241) promotes the release of gut peptides GLP-1, GIP, and PYY, which are involved in glucose and lipid metabolism, as well as weight loss [3] - Preclinical studies have shown that DA-1241 reduces hepatic steatosis, inflammation, and fibrosis while improving glucose control [3] - In Phase 1a, 1b, and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with type 2 diabetes mellitus (T2DM) [3] Upcoming Presentation - The poster presentation titled "Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improving Inflammation and Metabolism in the Liver" will be presented by Dr. Rohit Loomba at the AASLD meeting on November 10, 2025 [6]